<unk> , sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH).<unk>  and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. It is taken by mouth or administered intravenously.
Selexipag
Vosoritide
Vagisil
Prasugrel
Eteplirsen
Furegrelate
Snoezelen
Tezacaftor